Please login to the form below

Not currently logged in
Email:
Password:

pancreatic cancer

This page shows the latest pancreatic cancer news and features for those working in and with pharma, biotech and healthcare.

Pfizer gets first FDA nod for hedgehog inhibitor in AML

Pfizer gets first FDA nod for hedgehog inhibitor in AML

The small-molecule drug blocks part of the Sonic hedgehog pathway, which is also targeted by other cancer drugs including Roche’s Erivedge (vismodegib) and Novartis’ Odomzo (sonidegib) for basal cell ... Erivedge has been discontinued for AML and

Latest news

  • Soon-Shiong presents first data on cancer memory vaccine at SITC Soon-Shiong presents first data on cancer memory vaccine at SITC

    NK) cells, tumour antigens and drugs achieved tumour responses in heavily pre-treated patients with advanced cases of triple-negative breast cancer, head and neck cancer, and pancreatic cancer. ... checkpoint inhibitors – all designed to stimulate a

  • Q&A: Kate Pain Q&A: Kate Pain

    Randy was an American professor who was diagnosed with pancreatic cancer in 2006 and given between three to six months to live.

  • A look ahead to key trial readouts at ESMO A look ahead to key trial readouts at ESMO

    8040 in pancreatic cancer and a phase 1 study of the drug with CTLA-4 inhibitor MK-1308 in solid tumours. ... VEGF/FGF/PDGF inhibitor will give an update on lucitanib – also in HR+/HER2- breast cancer.

  • Lilly gets EMA nod for Verzenio in breast cancer Lilly gets EMA nod for Verzenio in breast cancer

    The company gave up on a plan to extend the use of abemaciclib into pancreatic cancer earlier this year, and suffered another setback in 2017 when the drug failed to meet ... the mark in the phase 3 JUNIPER study, which was intended to position the drug

  • Cancer Research UK to test Asterias’ lung cancer vaccine Cancer Research UK to test Asterias’ lung cancer vaccine

    Asterias isn’t the only biotech looking at telomerase as a cancer vaccine target, and this isn’t the first time that CRUK has backed such a product. ... The charity helped Roche carry out a phase III trial of its peptide-based GV1001 telomerase

More from news
Approximately 21 fully matching, plus 92 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    13 new targeted medicines that block the growth and spread of cancer by interfering with specific molecular targets. ... and ovarian cancer, and some tumours such as pancreatic and prostate cancers have proved resistant to current immunotherapies.

  • Finding the patient voice Finding the patient voice

    Mr Whitley took part in a pancreatic cancer drug trial in 2011.

  • Deal Watch February 2017 Deal Watch February 2017

    triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer.  . ... Licence. 358. AstraZeneca/ TerSera Therapeutics. Zoladex, goserelin acetate implant for prostate, breast cancer,

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    1. MM-398 a nanoliposomal irinotecan injection of for metastatic pancreatic cancer in phase III. ... 805. Curevac / Boehringer Ingelheim. Licence and collaboration. Messenger RNA vaccine (CV9202) in combination with afatininib and chemo-radiation for

  • Pharma deals during September 2014 Pharma deals during September 2014

    Baxter is licensing Merrimack's nanoliposomal injection of irinotecan which has orphan status in the US and the EU for metastatic pancreatic cancer, but does not have US rights. In contrast,

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics